explored the association of baseline NLR and PLR with prognosis in patients with HCC receiving specifically atezolizumab (a PD‐L1 inhibitor) plus bevacizumab, and the patients were also majorly from Europe and the United States. The gene discussed is CD274; the disease is hepatocellular carcinoma.